GLPwatch

Differentiating effects of the glucagon-like peptide-1 analogue exendin-4 in a human neuronal cell model.

Cell Mol Life Sci · 2010

Last updated 2026-05-28

In a human neuronal cell model, the GLP-1 drug exendin-4 increased the number of nerve projections and altered the structure of key cell components like actin and tubulin. It also enhanced electrical activity in the cells, including increased sensitivity of stretch-activated channels and higher currents for sodium and calcium, changes typical of more mature neurons.

AI summary of the abstract below.

JournalCell Mol Life Sci, 2010
Citations45
Relative citation ratio1.28
NIH percentile59
Molecules
Conditions studied Alzheimers, Parkinsons

Abstract

Glucagon-like peptide-1 (GLP-1) is an insulinotropic peptide with neurotrophic properties, as assessed in animal cell models. Exendin-4, a GLP-1 analogue, has been recently approved for the treatment of type 2 diabetes mellitus. The aim of this study was to morphologically, structurally, and functionally characterize the differentiating actions of exendin-4 using a human neuronal cell model (i.e., SH-SY5Y cells). We found that exendin-4 increased the number of neurites paralleled by dramatic changes in intracellular actin and tubulin distribution. Electrophysiological analyses showed an increase in cell membrane surface and in stretch-activated-channels sensitivity, an increased conductance of Na(+) channels and amplitude of Ca(++) currents (T- and L-type), typical of a more mature neuronal phenotype. To our knowledge, this is the first demonstration that exendin-4 promotes neuronal differentiation in human cells. Noteworthy, our data support the claimed favorable role of exendin-4 against diabetic neuropathy as well as against different neurodegenerative diseases.

Verbatim abstract via PubMed 20496097 ↗